Emi H. Caywood, MD


Primary Office

Nemours Children's Hospital, Delaware Nemours Children's Hospital, Delaware 1600 Rockland Road Wilmington, DE 19803 Appointment: (800) 416-4441

Other Offices

Get to Know Me

With a passion for science and my desire to always work with people, I decided to pursue becoming a doctor after college. Today, I’m incredibly fortunate to help treat children with a variety of cancers and blood disorders – including eye tumors.

Why I Treat Children

I’m amazed by their resilience, honesty and innocence – and I want to help make their life the best it can possibly be The children I treat didn’t ask for the medical conditions they have, and they deserve the best that is in me.

Education & Training


  • Pediatric Hematology/Oncology - Johns Hopkins University, 2009


  • Pediatrics - Georgetown University Hospital (MedStar Health), 2005

Medical/Dental School

  • MD - University of Medicine and Dentistry of New Jersey, 2002

Board Certifications

  • American Board of Pediatrics/Pediatric Hematology-Oncology

Awards & Recognition

  • 2014 Delaware Today magazine, Top Doctors
  • 2013 Hyundai Hope on Wheels Grant Scholar
  • 2008 Fellow Award Finalist, American Society of Hematology

Insurance Accepted

  • Aetna Better Health PA Kids HMO
  • Aetna HMO
  • Aetna PPO/POS/EPO
  • Amerihealth Caritas Delaware
  • Carefirst MD Community Health Plan Mcaid
  • Cigna/Great West HMO EPO POS
  • Cigna/Great West PPO
  • Delaware First Health
  • Delaware Medicaid/Diamond State
  • Delaware Medicare
  • Devon Health Services
  • Fidelis Care NJ Medicaid HMO
  • First Health/Affordable PPO
  • Geisinger Health Plan Commercial
  • Global Medical Managment DE/PA
  • Health Partners Medicaid/Kidz Partner HMO
  • Highmark Blue Cross Blue Shield of Delaware
  • Highmark Blue Cross Blue Shield of Pennsylvania
  • Highmark Medicaid Health Options
  • Horizon Blue Cross Blue Shield of New Jersey
  • Independance Blue Cross/Amerihealth/Keystone Health Plan
  • Insurance Administrators of America
  • INTEGRA Administrative Group (ClaimsBridge)
  • Interlink Transplant
  • Keystone First Medicaid HMO
  • Lifetrac Transplant
  • Maryland Medicaid
  • Multiplan PPO
  • New Jersey Medicaid
  • Pennsylvania Medicaid
  • Plan Vista/NPPN PPO
  • Preferred Healthcare PPO
  • Private Health Care Systems (PHCS)
  • Qualcare HMO/POS/PPO
  • Star Healthcare Network
  • Three Rivers Provider Network
  • Tricare/Humana Military Health Services/CHAMPVA
  • United Healthcare of the Mid-Atlantic
  • US Family Health Plan
  • Wellpoint Maryland Medcaid

  • Anemia
  • Blood and Bone Marrow Transplantation
  • Blood Disorders
  • Cancer Care
  • Leukemia
  • Lymphoma
  • Neuroblastoma
  • Neutropenia
  • Retinoblastoma

Medical Interests

  • Acute myeloid leukemia (AML)

  • γδ CD8+ T cells and novel genetic variants in ZAP70 deficiency; Pediatric Allergy and Immunology; (2023).

    View Full Publication
  • Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium; The Lancet; (2023).

    View Full Publication
  • Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia; Infection Control & Hospital Epidemiology; (2023).

    View Full Publication
  • Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias; Blood Advances; (2023).

    View Full Publication
  • The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions; Journal of Allergy and Clinical Immunology; (2023).

    View Full Publication
  • Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC; Blood; (2022).

    View Full Publication
  • Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease; Blood; (2022).

    View Full Publication
  • A clinician’s guide to HLA matching in allogeneic hematopoietic stem cell transplant; Human Immunology; (2022).

    View Full Publication
  • Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management after Chemotherapy for Pediatric Acute Myeloid Leukemia; JAMA Network Open; (2021).

    View Full Publication
  • Immune profile differences between chronic GVHD and late acute GVHD: Results of the ABLE/PBMTC 1202 studies; Blood; (2020).

    View Full Publication
  • Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey; Frontiers in Immunology; (2020).

    View Full Publication
  • Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria; Blood; (2019).

    View Full Publication
  • The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018); Journal of Allergy and Clinical Immunology; (2019).

    View Full Publication

    View Full Publication
  • Unilateral retinoblastoma managed with intravenous chemotherapy versus intra-arterial chemotherapy. Outcomes based on the international classification of retinoblastoma; Asia-Pacific Journal of Ophthalmology; (2016).

    View Full Publication
  • Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: A case report; Biomarker Research; (2016).

    View Full Publication
  • Retinoblastoma control with primary intra-arterial chemotherapy: Outcomes before and during the intravitreal chemotherapy era; Journal of Pediatric Ophthalmology and Strabismus; (2016).

    View Full Publication
  • Challenges in converting Acute Myeloid Leukemia (AML) genomics into AML clinical trials; Journal of Clinical Oncology; (2015).

    View Full Publication
  • Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: Evidence from four decades of US population data; Cancer Epidemiology; (2015).

    View Full Publication
  • Intra-arterial chemotherapy for retinoblastoma in 70 eyes: Outcomes based on the international classification of retinoblastoma; Ophthalmology; (2014).

    View Full Publication
  • Targeted retinoblastoma management: When to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy; Current Opinion in Ophthalmology; (2014).

    View Full Publication
  • Abnormalities of the large ribosomal subunit protein, rpl35a, in diamond-blaekfan anemia; Blood; (2008).

    View Full Publication

  • English